1.1050
25-November-24 12:38:36
15 minutes delayed
Stocks
+0.0250
+2.31%
Today's range
1.0600 - 1.1200
ISIN
N/A
Source
NASDAQ
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
12 Jan 2021 06:05:00 By Nasdaq GlobeNewswire
Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering
06 Jan 2021 06:05:00 By Nasdaq GlobeNewswire